Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
Apoptosis
Inhibitor of anti-apoptosis proteins
Multiple myeloma
SMAC mimetics
Journal
Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
11
07
2023
revised:
23
10
2023
accepted:
16
11
2023
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
11
12
2023
Statut:
ppublish
Résumé
Overexpression of inhibitor of apoptosis (IAP) proteins is associated with poor prognosis. In multiple myeloma (MM), the IAP inhibitors (IAPi), LCL161, have been evaluated in preclinical and clinical settings but are not fully effective. Among IAPs, XIAP has the strongest anti-apoptotic function with direct binding activity to caspases and cIAP1 and cIAP2 are positive regulator of NF-κB signaling. Prior IAPi such as LCL161 has high affinity to cIAP1 and cIAP2 resulting in inferior inhibiting activity against XIAP. A novel dimeric IAPi, AZD5582 (C
Identifiants
pubmed: 38081681
pii: S1347-8613(23)00065-8
doi: 10.1016/j.jphs.2023.11.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-36Informations de copyright
Copyright © 2023 The Authors. Production and hosting by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare they have no conflict of interest to disclose.